Analytical Data
-
基因名
CYP4B1
- Application
-
别名
CP4B1_HUMAN; CYP4B1; CYPIVB1; Cytochrome P450 4B1; Cytochrome P450 family 4 subfamily B polypeptide 1; Cytochrome P450 subfamily IVB polypeptide 1; Cytochrome P450-HP; Microsomal monooxygenase; P450HP
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P13584
-
表达区间
1-512aa
-
氨基酸序列
MVPSFLSLSFSSLGLWASGLILVLGFLKLIHLLLRRQTLAKAMDKFPGPPTHWLFGHALEIQETGSLDKVVSWAHQFPYAHPLWFGQFIGFLNIYEPDYAKAVYSRGDPKAPDVYDFFLQWIGRGLLVLEGPKWLQHRKLLTPGFHYDVLKPYVAVFTESTRIMLDKWEEKAREGKSFDIFCDVGHMALNTLMKCTFGRGDTGLGHSRDSSYYLAVSDLTLLMQQRLVSFQYHNDFIYWLTPHGRRFLRACQVAHDHTDQVIRERKAALQDEKVRKKIQNRRHLDFLDILLGARDEDDIKLSDADLRAEVDTFMFEGHDTTTSGISWFLYCMALYPEHQHRCREEVREILGDQDFFQWDDLGKMTYLTMCIKESFRLYPPVPQVYRQLSKPVTFVDGRSLPAGSLISMHIYALHRNSAVWPDPEVFDSLRFSTENASKRHPFAFMPFSAGPRNCIGQQFAMSEMKVVTAMCLLRFEFSLDPSRLPIKMPQLVLRSKNGFHLHLKPLGPGSGK
-
分子量
82.06 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP4B1 is a member of the cytochrome P450 enzyme family, which plays a crucial role in the metabolism of various endogenous and exogenous compounds. Research into CYP4B1 has gained attention due to its involvement in the hydroxylation of fatty acids and the metabolism of drugs, affecting pharmacokinetics and toxicology. Its unique substrate specificity and polymorphic nature suggest that variations in CYP4B1 expression may influence individual responses to medications and susceptibility to diseases, particularly in relation to drug-induced toxicity. Studies have indicated that CYP4B1 may also be implicated in the metabolic activation of certain procarcinogens, raising concerns about its potential role in cancer development. The recombinant expression of CYP4B1 provides a valuable tool for understanding its enzymatic properties and the molecular mechanisms underlying its function. By generating recombinant CYP4B1 proteins, researchers can investigate substrate interactions, characterize enzyme kinetics, and explore the effects of genetic variations on enzyme activity. This research can pave the way for the development of personalized medicine approaches by identifying individuals at risk for adverse drug reactions. As such, the study of CYP4B1 not only enhances our understanding of drug metabolism but also contributes to the broader field of pharmacogenomics, highlighting the importance of genetic factors in drug therapy and disease susceptibility. The ongoing exploration of CYP4B1's role in biotransformation processes has significant implications for drug development, toxicology, and precision medicine, emphasizing the need for further elucidation of its function and regulation in human health and disease.
